At EMD Serono, we currently dedicate more that two-thirds of our R&D investment to oncology and immuno-oncology. Through biomarker-driven research, we aim to develop personalized treatments that address hard-to-treat cancers.
We are building a strong pipeline in oncology for an immuno-oncology program that includes potential new medicines in more than 15 difficult-to-treat tumour types with high unmet patient needs.
Ultimately, we aspire to discover and develop diverse treatment options and new approaches to cancer care. Together, we are building a strong position in this emerging area to help those with cancer, live longer, healthier lives.
When great minds get together, they inspire each other. Our collaborative culture proves it. By working a better way—sharing ideas, voicing opinions, giving feedback and lending support—we get better results.View All Jobs
You are now leaving the website of Merck KGaA, Darmstadt, Germany’s biopharma business. This link may lead to a resource maintained by third parties over whom we have no control. As such, we are not responsible for and makes no representation as to the accuracy or any other aspect of such resource or the privacy practices of such third party. Providing links to a third party website does not constitute an endorsement by our company of such website or the information or products presented on such website.